Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China · Delayed Price · Currency is CNY 6.75
-0.08 (-1.17%)
Apr 29, 2026, 3:04 PM CST
Beijing SL Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 623.64 | 652.74 | 1,005 | 1,033 | 1,199 |
Other Revenue | - | 7.68 | 12.98 | 17.05 | 16.05 |
| 623.64 | 660.42 | 1,018 | 1,050 | 1,215 | |
Revenue Growth (YoY) | -5.57% | -35.15% | -3.03% | -13.55% | 9.17% |
Cost of Revenue | 236.09 | 212.09 | 188.81 | 156.96 | 183.57 |
Gross Profit | 387.56 | 448.33 | 829.55 | 893.21 | 1,031 |
Selling, General & Admin | 274.7 | 259.91 | 405.65 | 546.76 | 585.32 |
Research & Development | 115.4 | 149.62 | 177.11 | 161.65 | 196.15 |
Other Operating Expenses | 0.11 | 1.66 | 2.89 | 9.2 | 11.22 |
Operating Expenses | 390.21 | 420.68 | 609.45 | 749.55 | 818.94 |
Operating Income | -2.65 | 27.65 | 220.1 | 143.66 | 212.3 |
Interest Expense | - | - | - | -0.1 | -0.23 |
Interest & Investment Income | 13.38 | 21.52 | 48.46 | 93.84 | 112.26 |
Currency Exchange Gain (Loss) | - | -0.9 | 0.7 | 0.02 | 0.05 |
Other Non Operating Income (Expenses) | -615.17 | -1.66 | -1.83 | -0.21 | -0.23 |
EBT Excluding Unusual Items | -604.44 | 46.61 | 267.44 | 237.21 | 324.14 |
Gain (Loss) on Sale of Investments | 353.81 | -172.29 | 205.21 | 19.49 | 113.58 |
Gain (Loss) on Sale of Assets | -0.05 | 0 | 0.01 | 0.21 | 3.22 |
Asset Writedown | -27.46 | - | - | -0 | -0.02 |
Other Unusual Items | - | -8.07 | -7.76 | 2.45 | 16.91 |
Pretax Income | -278.14 | -133.75 | 464.89 | 259.35 | 457.84 |
Income Tax Expense | 70.06 | -58.46 | 49.94 | 31.01 | 36.51 |
Earnings From Continuing Operations | -348.21 | -75.29 | 414.96 | 228.34 | 421.33 |
Minority Interest in Earnings | 1.01 | 1.22 | 1.73 | 6.06 | 4.61 |
Net Income | -347.2 | -74.07 | 416.69 | 234.4 | 425.94 |
Net Income to Common | -347.2 | -74.07 | 416.69 | 234.4 | 425.94 |
Net Income Growth | - | - | 77.77% | -44.97% | 16.79% |
Shares Outstanding (Basic) | 1,021 | 1,058 | 1,016 | 1,019 | 1,039 |
Shares Outstanding (Diluted) | 1,021 | 1,058 | 1,016 | 1,019 | 1,039 |
Shares Change (YoY) | -3.49% | 4.11% | -0.28% | -1.90% | 2.55% |
EPS (Basic) | -0.34 | -0.07 | 0.41 | 0.23 | 0.41 |
EPS (Diluted) | -0.34 | -0.07 | 0.41 | 0.23 | 0.41 |
EPS Growth | - | - | 78.26% | -43.90% | 13.89% |
Free Cash Flow | 64.69 | -121.89 | 241.84 | 226.33 | 227.72 |
Free Cash Flow Per Share | 0.06 | -0.12 | 0.24 | 0.22 | 0.22 |
Dividend Per Share | - | 0.020 | 0.150 | 0.100 | 0.100 |
Dividend Growth | - | -86.67% | 50.00% | - | - |
Gross Margin | 62.14% | 67.89% | 81.46% | 85.05% | 84.89% |
Operating Margin | -0.43% | 4.19% | 21.61% | 13.68% | 17.48% |
Profit Margin | -55.67% | -11.21% | 40.92% | 22.32% | 35.06% |
Free Cash Flow Margin | 10.37% | -18.46% | 23.75% | 21.55% | 18.75% |
EBITDA | 164.13 | 180.59 | 365.5 | 257.17 | 311.97 |
EBITDA Margin | 26.32% | 27.34% | 35.89% | 24.49% | 25.68% |
D&A For EBITDA | 166.78 | 152.94 | 145.4 | 113.51 | 99.67 |
EBIT | -2.65 | 27.65 | 220.1 | 143.66 | 212.3 |
EBIT Margin | -0.43% | 4.19% | 21.61% | 13.68% | 17.48% |
Effective Tax Rate | - | - | 10.74% | 11.96% | 7.98% |
Revenue as Reported | - | 660.42 | 1,018 | 1,050 | 1,215 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.